Determinants of platelet count are different in patients with compensated and decompensated cirrhosis

被引:18
|
作者
Latorre, Raquel [1 ,2 ]
Vaquero, Javier [1 ,2 ]
Rincon, Diego [1 ,2 ]
Puerto, Marta [1 ,2 ]
Ponce, Maria D. [3 ]
Sarnago, Fernando [4 ]
Matamoros, Jose A. [1 ]
Ramon, Enrique [3 ]
Elizaga, Jaime [4 ]
Banares, Rafael [1 ,2 ,5 ]
Ripoll, Cristina [1 ,2 ]
机构
[1] Hosp Gen Gregorio Maranon, Inst Invest Sanit Gregorio Maranon, Liver Unit, Dept Digest Dis, Calle Dr Esquerdo 46, Madrid 28007, Spain
[2] Hosp Gen Gregorio Maranon, CIBERehd, Madrid, Spain
[3] Hosp Gen Gregorio Maranon, Dept Radiol, Madrid, Spain
[4] Hosp Gen Gregorio Maranon, Dept Cardiol, Madrid, Spain
[5] Univ Complutense Madrid, Fac Med, Madrid, Spain
关键词
end-stage liver disease; liver insufficiency; pathophysiology; portal hypertension; thrombocytes; HEPATIC VENOUS-PRESSURE; CHRONIC LIVER-DISEASE; SERUM THROMBOPOIETIN LEVELS; CHRONIC VIRAL-HEPATITIS; PORTAL-HYPERTENSION; THROMBOCYTOPENIC PATIENTS; C-KIT; HYPERSPLENISM; GRADIENT; BINDING;
D O I
10.1111/liv.12908
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Different mechanisms including portal hypertension and hypersplenism have been involved in the development of thrombocytopenia in cirrhosis. However, the relative contribution of each one is unknown. The aim was to evaluate simultaneously different mechanisms that determine platelet count in cirrhosis. Methods: Cross-sectional study including cirrhotics (n = 120) with hepatic venous pressure gradient (HVPG) measurement. Samples were obtained from peripheral (P) veins to evaluate thrombopoietin (TPO), stem cell factor, hepatocyte growth factor (HGF), tumour necrosis factor, interleukin-(IL6) and (IL11) and from hepatic (H) veins to evaluate TPO. A subgroup (n = 72) had spleen volume estimation. H and P-TPO were also measured in non-cirrhotic patients (n = 15). Results: Patients (Child A: 55, B: 43, C: 22) had a median platelet count of 81 000/mm 3 (IQR 60 500, 110 750), which correlated with spleen volume (r = -0.38, P < 0.001). Platelets were associated also to HVPG (r = -0.47, P = 0.004) and P-TPO (r = 0.31, P = 0.050) only in compensated patients. H-TPO decreased, and the proportion of patients with P-TPO > H-TPO increased, with the presence and the severity of liver disease. H-TPO was correlated with liver function (bilirubin r = -0.350, P < 0.001 and international normalized ratio r = -0.227, P = 0.011). Patients with H-TPO < P-TPO had higher levels of IL-11 and HGF. Conclusion: Platelet count in cirrhosis is associated mainly to spleen volume, although portal hypertension as estimated by HVPG and liver function plays a significant role in compensated patients. H-TPO and the proportion of patients with P-TPO > H-TPO were associated to the presence and severity of liver disease.
引用
收藏
页码:232 / 239
页数:8
相关论文
共 50 条
  • [1] PLATELET COUNT AS A SCREENING TOOL FOR COMPENSATED CIRRHOSIS
    Surana, Pallavi
    Hercun, Julian
    Takyar, Varun
    Kleiner, David E.
    Heller, Theo
    Koh, Christopher
    HEPATOLOGY, 2020, 72 : 624A - 625A
  • [2] Outcomes for Patients on DOACs in Compensated and Decompensated Cirrhosis
    Aslam, Aysha
    Gombar, Saurabh
    Kwo, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S893 - S894
  • [3] Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis
    Berzigotti, Annalisa
    Seijo, Susana
    Arena, Umberto
    Abraldes, Juan G.
    Vizzutti, Francesco
    Garcia-Pagan, Juan Carlos
    Pinzani, Massimo
    Bosch, Jaime
    GASTROENTEROLOGY, 2013, 144 (01) : 102 - U206
  • [4] Platelet Count and Survival of Patients With Compensated Cirrhosis and Small Hepatocellular Carcinoma Treated With Surgery
    Giannini, Edoardo G.
    Savarino, Vincenzo
    HEPATOLOGY, 2014, 59 (04) : 1649 - 1649
  • [5] Prognostic indicators of survival in patients with compensated and decompensated cirrhosis
    Zipprich, Alexander
    Garcia-Tsao, Guadalupe
    Rogowski, Sebastian
    Fleig, Wolfgang E.
    Seufferlein, Thomas
    Dollinger, Matthias M.
    LIVER INTERNATIONAL, 2012, 32 (09) : 1407 - 1414
  • [6] Empagliflozin is safe and tolerable in patients with compensated or decompensated cirrhosis
    Shen, I.
    Danta, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 66 - 67
  • [7] BASELINE PLATELET COUNT PREDICTS THE OCCURRENCE OF DECOMPENSATED EVENTS IN PATIENTS WITH HEPATITIS C-RELATED COMPENSATED CIRRHOSIS WHO ACHIEVED SUSTAINED VIROLOGIC RESPONSE
    Tahata, Yuki
    Sakamori, Ryotaro
    Yamada, Ryoko
    Ohkawa, Kazuyoshi
    Hiramatsu, Naoki
    Hagiwara, Hideki
    Oshita, Masahide
    Tamura, Shinji
    Imai, Yasuharu
    Kodama, Takahiro
    Hikita, Hayato
    Tatsumi, Tomohide
    Takehara, Tetsuo
    HEPATOLOGY, 2020, 72 : 526A - 526A
  • [8] Mucosal and Fecal Microbiota in Patients With Compensated and Decompensated Liver Cirrhosis
    Tedjo, Danyta
    Pijls, Kirsten
    Koek, Ger
    Budding, Andries E.
    Savelkoul, Paul
    Masclee, Ad
    Penders, John
    Jonkers, Daisy
    GASTROENTEROLOGY, 2016, 150 (04) : S219 - S220
  • [9] Abnormal hemorheological properties in patients with compensated and decompensated hepatic cirrhosis
    Anwar, MA
    Rampling, MW
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2003, 29 (02) : 95 - 101
  • [10] Prognostic factors in compensated and decompensated cirrhosis
    Ripoll C.
    Zipprich A.
    Garcia-Tsao G.
    Current Hepatology Reports, 2014, 13 (3) : 171 - 179